Twist Bioscience's upside is still quite nicely linked to AI-enabled design and discovery despite its run. Citrini acknowledges that run; Twist is hardly asymmetric or underappreciated here. x.com 

Twist Bioscience could benefit as cheaper AI hypothesis generation and validation make physical experiments the bottleneck. It is currently the purest Anthropic-related biotech beneficiary in this view because Twist handles those experiments. More efficient hypothesis work may eventually ease even that bottleneck, but it is too early to give up on the opportunity. x.com 

Twist Bioscience looks more like a bubble than an investment case, even though it could benefit as AI multiplies drug candidates and pushes value up the biotech chain. It led the 2021 biotech bubble and still loses money, so buyers pay for the story, not the business. The same AI thesis is simpler and cheaper to own in vertical market software, through serial acquirers such as Constellation Software and Topicus, which gain more acquisition targets as software gets cheaper to build. x.com 

Twist Bioscience has real explosive upside in the AI science basket because it makes biology programmable. Its Anthropic partnership, with Claude in the loop, is already rerating the stock, and it just opened a wet lab in San Francisco. AI is moving from code into the physical sciences, and despite the jump on Google news, it is still early. x.com 

China SXT Pharmaceuticals is a short-squeeze candidate: short interest exceeds 20%, institutional ownership exceeds 100%, no shares are left to borrow and the cost to borrow is over 500%. It has the same setup as other low-float, high-short-interest plays; after coiling all day, a pop on incoming volume is only a matter of time because shorts are trapped. x.com  x.com 

Twist Bioscience is not a bet worth taking at about 25x sales. @FredaDuan's pitch that AI drug discovery makes it a bottleneck trade, with Twist expecting triple-digit growth in AI-enabled drug-discovery orders in FY26 and again in FY27, is clickbait. x.com  x.com 

Therapeutics and genomics are a hot theme that retail traders, focused on AI and software, have not yet noticed. Healthcare, drugs and biotech have been strong for the last few months. Favorites in the group are Revolution Medicines, Twist Bioscience, Halozyme and TG Therapeutics. x.com 

Moderna's mRNA vaccine news and Twist Bioscience's partnership with Anthropic could spark the cancer and genomics theme across treatments, diagnostics and tools, lifting Personalis, Guardant Health, Twist, HTFL, NeoGenomics and genomics stocks broadly. x.com 

AI drug-discovery picks and shovels such as Ginkgo Bioworks, 10x Genomics, Twist Bioscience and Grail are priced on a fantasy, and secondary offerings are coming. The bet that AI will solve cancers and rare diseases within months ignores how drug discovery, regulation and trial enrollment actually work. Unlike the semiconductor comparison, these businesses have not inflected, mostly burn cash, trade at 20-30x sales and need equity to fund themselves. Buyers here become their liquidity. x.com  … Show more

Wendy's, Xerox and Icahn Enterprises are set up for a short squeeze. They are the only stocks with over 30% short interest that pay dividends above 7%, so shorts pay heavily to stay short and lose more if prices rise. All three are in Stage 2 uptrends, and Wendy's and Xerox are retesting recent high-volume breakouts. A short-covering summer could start if the market breaks higher out of its consolidation. x.com